

**February 14, 2025**

**To,**

The Chief General Manager Listing  
Operation,  
BSE Limited,  
20th Floor, P. J. Towers, Dalal Street, Mumbai – 400 001.

Scrip Code: 524743

**Dear Sir/ Madam,**

**Sub: Integrated Filing (Financials) for the quarter ended 31st December 2024**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024, read with BSE Circular No.20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 02 January 2025 we are submitting herewith the Integrated Filing (Financials) for the quarter and period ended 31 December 2024.

Please take on record.

Thanking You,

Yours Truly,

**For FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



**ARAVINDKUMAR V**

**COMPANY SECRETARY & COMPLIANCE OFFICER**



**INTEGRATED FILING (FINANCIALS) FOR THE QUARTER ENDED 31ST DECEMBER 2024**

<b>S No.</b>	<b>PARTICULARS</b>	<b>REMARKS</b>
<b>1</b>	Unaudited financial results for the quarter and period ended 31 December 2024 (Standalone and Consolidated)	Enclosed as Annexure
<b>2</b>	Statement on Deviation or Variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.:	Not applicable
<b>3</b>	Format for disclosing outstanding default on loans and debt securities	No default. Hence not applicable.
<b>4</b>	Format for disclosure of related party transactions	Not applicable for this quarter
<b>5</b>	Statement on impact of audit qualifications (for audit report with modified opinion) submitted alongwith annual audited financial results (standalone and consolidated separately)	Not applicable for this quarter

FISCHER MEDICAL VENTURES LIMITED (formerly known as Fischer Chemic Limited)  
CIN: L86900MH1993PLC288371

Regd Off: 104, First Floor Raghuleela Mega Mall Behind Poisar Depot Kundivali West, Mumbai, Maharashtra, India, 400067

Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India

Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 31.12.2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

SL NO	PARTICULARS	STANDALONE						CONSOLIDATED					
		Quarter ended			Nine Months ended		Year ended	Quarter ended			Nine Months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	Revenue from Operations	-	-	-	-	18.81	1152.83	1174.85	3965.53	-	6,152.45	-	2098.13
II	Other Income	86.58	81.96	1.37	280.76	2.70	75.05	37.81	22.35	-	134.34	-	50.12
III	Total Income (I + II)	86.58	81.96	1.37	280.76	21.51	1227.88	1212.67	3987.88	-	6,286.79	-	2148.25
IV	Expenses												
	Cost of Materials consumed	-	-	-	-	-	1072.36	0.00	-	-	-	-	1573.80
	Purchase of stock-in-trade	-	6.50	-	6.50	-	-	217.71	4086.33	-	6055.87	-	7.87
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	(6.50)	-	(6.50)	-	-	536.19	(473.77)	-	-827.97	-	63.74
	Employee Benefits Expense	2.90	4.18	2.68	9.61	4.21	5.50	74.64	50.60	-	164.55	-	38.09
	Finance Costs	-	-	-	-	1.58	1.58	6.69	4.86	-	24.05	-	6.76
	Depreciation and amortisation expenses	2.75	0.05	0.02	2.86	0.02	0.08	55.71	28.81	-	112.25	-	18.21
	Other Expenses	19.18	31.44	11.91	59.31	24.48	94.49	296.71	252.98	-	678.64	-	228.66
	Total Expenses	24.83	35.67	14.62	71.78	30.29	1174.01	1187.65	3949.81	-	6207.39	-	1937.13
V	Profit / (Loss) before Exceptional Items & Tax (III - IV)	61.75	46.29	(13.25)	208.98	(8.79)	53.87	25.01	38.07	-	79.40	-	211.12
VI	Share of profit/(loss) of Associates							-12.57	(17.05)		(38.34)		
VII	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	0.00
VIII	Profit / (Loss) before Tax (V - VI - VII)	61.75	46.29	(13.25)	208.98	(8.79)	53.87	12.44	21.02	-	41.06	-	211.12
IX	Tax Expense												
	Current Tax	(42.00)	5.00	0.00	(54.00)	0.00	(3.00)	(42.00)	5.00	-	(54.00)	-	(3.00)
	Deferred Tax (Asset)/Liability	0.17	(0.01)	(0.03)	0.14	(10.57)	(10.59)	0.17	3.31	-	2.51	-	(24.33)
X	Profit / (Loss) for the period from continuing Operations (VIII-IX)	19.92	51.28	(13.28)	155.12	(19.36)	40.28	(29.39)	29.33	-	(10.43)	-	183.79
XI	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	Tax Expense of Discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) from Discontinued Operations after Tax (XI - XII)	-	-	-	-	-	-	-	-	-	-	-	-
XIV	Profit / (Loss) for the period (X + XIII)	19.92	51.28	(13.28)	155.12	-19.36	40.28	(29.39)	29.33	-	(10.43)	-	183.79
XV	Other Comprehensive Income												
	A. Items that will not be reclassified to Profit / (Loss)												
	(i) Remeasurement of defined benefit plan - Actuarial gains / (Losses)	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income Tax relating on above	-	-	-	-	-	-	-	-	-	-	-	-
	(iii) Equity instruments through other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income-Total	-	-	-	-	-	-	-	-	-	-	-	-
XVI	Total comprehensive income for the period (comprising profit/(Loss) for the period (after tax) and other comprehensive income for the period(after tax))	-	-	-	-	-	-	-	-	-	-	-	-
XVII	Paid up Equity Share Capital (Face Value Re.10/-)	5350.00	5350.00	17.20	5350.00	17.20	5350.00	5350.00	5350.00	17.20	5350.00	17.20	5350.00
XVIII	Other Equity excl. revaluation reserves as at previous balance sheet date						2530.79						2674.30
XIX	Earnings Per Share (EPS)												
	(a) Basic EPS From Continuing Operations (In Rs.)	0.04	0.10	(0.76)	0.29	(1.11)	0.36	(0.05)	0.05	-	(0.02)	-	1.65
	(b) Basic EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-
	(c) Diluted EPS From Continuing Operations (In Rs.)	0.04	0.09	(0.76)	0.28	(1.11)	0.36	(0.05)	0.05	-	(0.02)	-	1.08
	(d) Diluted EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-

Notes:

- These unaudited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements", the previous year quarter ended, There is No comparatives of previous year's figures as on quarter and period ended 30th Sept 2023.
- Company has not presented comparative financial information for the quarter and year-to-date periods ended December 31, 2023, as the acquisitions that form part of the consolidated financial statements were not completed in the corresponding periods of the previous year. Consequently, no consolidation was undertaken during that time, rendering comparative figures unavailable.
- Your Company, has made an investment in Wondertech Medical Solutions Pvt. Ltd., which was incorporated on November 13, 2024, as a direct subsidiary of the Company.
- The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14-02-2025.
- During the second quarter, the Company completed the incorporation of Flynncare Health Innovations Pvt. Ltd., Fischer Hospitality Sdn. Bhd., FMV International Ventures PTE Ltd., and FMV Healthcare PTE Ltd. However, as there were no transactions in both the previous and current quarters, these entities have been considered for consolidation purposes but do not have any impact on the consolidated financial figures.
- The Statutory Auditor of the Company have carried out a Limited Review of the above Standalone and Consolidated Financial Results for the Quarter / Half Year ended 31.12.2024 and their report was placed before the Board.
- The above is an extract of the detailed format of Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results are available in the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and Company's website at www.fischermv.com

// BY ORDER OF BOARD //



For Fischer Medical Ventures Limited  
(Formerly known as Fischer Chemic Limited)

*[Signature]*  
Mr. Ravindran Govindan  
Chairman & Managing Director

Date : 14/02/2025

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to date of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To**

**The Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended **31<sup>st</sup> December 2024** and year to date result for the period from **1<sup>st</sup> April 2024 to 31<sup>st</sup> December 2024** being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') , and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any

material misstatement.

Our Opinion is not modified in respect of these matters.

**For Bilimoria Mehta & Co.**  
**Chartered Accountants**  
**Firm Reg. No. 101490W**

PRAKASH  
RAMNIKLAL  
MEHTA

Digitally signed by  
PRAKASH RAMNIKLAL  
MEHTA  
Date: 2025.02.14  
17:57:54 +05'30'

**CA Prakash Mehta**  
**Partner**  
**Membership no. 030382**  
UDIN: 25030382BMMIID5165  
Place: Mumbai  
Date: 14-02-2025

**Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 31st December 2024 and consolidated year to date results for the period 1 April 2024, to 31st December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
5. Based on our review conducted and procedures performed and upon consideration of the review reports of other auditors below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs. 12,470.73 Lakhs as at 31st December 2024, and year-to-date total revenues of Rs 6,374.64 lakhs and year-to-date total comprehensive loss of Rs 167.03 lakhs, as considered in the Statement. The independent auditor's reports on interim financial results and other financial information of these entities have been furnished to us by management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

**For Bilimoria Mehta & Co,**  
**Chartered Accountants**  
**ICAI Firm Registration No.: 101490W**

PRAKASH  
RAMNIKLAL  
MEHTA

Digitally signed by  
PRAKASH RAMNIKLAL  
MEHTA  
Date: 2025.02.14 17:56:15  
+05'30'

**CA Prakash Mehta**  
**Partner**  
**Membership No: 030382**  
UDIN: 25030382BMIIIC7873  
Place: Mumbai  
Date: 14-02-2025

**ANNEXURE-1**

**List of Entities included in the statement:**

<b>Sr no</b>	<b>Particulars</b>	<b>Stakes</b>	<b>Status</b>
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer Medical Ventures Limited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited